Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L6 pseudogene 1 (RPL6P1) is a **processed pseudogene** in humans, identified by gene symbols such as RPL6P1 and RPL6_1_44. Pseudogenes are genomic sequences similar to known genes but generally non-functional, lacking the ability to code for a full, active protein. RPL6P1 arose by retrotransposition of the ribosomal protein L6 mRNA, resulting in a sequence homologous to RPL6 but which is not transcribed into a functional protein product. Like other processed pseudogenes of ribosomal protein genes, RPL6P1 is not known to have any active biological function, disease role, or pharmacological relevance. **Key context and clarification:** - RPL6P1 is not the same as the functional *RPL6* gene, which encodes the ribosomal protein L6, a structural component of the 60S ribosomal subunit involved in protein synthesis. - *RPL6* gene and its protein product participate in essential cellular functions, but *RPL6P1* is a non-functional byproduct of genome evolution, and not a target for drugs or therapeutic research. - Pseudogenes like RPL6P1 are often cataloged simply for reference and do not have molecular, clinical, or therapeutic utility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L6 pseudogene 1 (RPL6P1).